Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: B.REVERE who wrote (4176)	7/10/1998 10:13:00 AM
From: B.REVERE	Read Replies (2) \| Respond to of 9523

[MONEY FLOW]-----a key indicator of where a stock is headed is moneyflow or the volume of shares being bought at the ask as opposed to being sold at the bid. The first half hour of trading, positive money flow exceeded negative by about a 5:1 ratio. The institutions were busy buying on any dip and you can't blame them. This is the only defensive big cap growth stock that will continue to meet or exceed its numbers for the next 2 decades. Selling was brought on by call writers who closed out positions for next friday's options expirations. Later, BR

To: B.REVERE who wrote (4176)	7/10/1998 11:22:00 AM
From: Anthony Wong	Read Replies (1) \| Respond to of 9523

"Outperform" at Morgan Stanley DW, Schroder & Co Pfizer Inc. Maintained 'Outperform' at Morgan Stanley DW Bloomberg News July 10, 1998, 9:07 a.m. ET Princeton, New Jersey, July 10 (Bloomberg Data) -- Pfizer Inc. (PFE US) was maintained ''outperform'' by analyst Paul A. Brooke at Morgan Stanley Dean Witter. The 12-month target price is $120.00 per share. -- Andrew Bekoff in Princeton, New Jersey, (609)279-3652 Andrew Bekoff in Princeton, New Jersey, (609)279-3652 Pfizer Inc. Maintained 'Outperform' at Schroder & Co Bloomberg News July 10, 1998, 9:07 a.m. ET Princeton, New Jersey, July 10 (Bloomberg Data) -- Pfizer Inc. (PFE US) was maintained ''outperform'' by analyst Jami Rubin at Schroder & Co. The 12-month target price is $130.00 per share.